

Potential for Broad Patients Benefits with Significant Upcoming Milestones

PROGRAM	MODALITY/TARGET	INDICATION	DISCOVERY	PRECLINICAL	PHASE 1/1B	PHASE 2	PHASE 3	WORLDWIDE OR GEOGRAPHIC PARTNER
SUTRO-LED PROGRAMS								
Luveltamab tazevibulin (Luvelta, STRO-002)	FR α Antibody-Drug Conjugate (ADC)	Ovarian Cancer	[Progress bar from Discovery to Phase 3]					
		Ovarian Cancer (bevacizumab combo)	[Progress bar from Discovery to Phase 1/1B]					
		Endometrial Cancer	[Progress bar from Discovery to Phase 1/1B]					
		CBF/GLIS2 Pediatric AML	[Progress bar from Discovery to Phase 2]					
		NSCLC	[Progress bar from Discovery to Phase 1/1B]					
STRO-004	Tissue Factor ADC	Solid Tumors	[Progress bar from Discovery to Phase 1/1B]					
PARTNER PROGRAMS								
VAX-24	24-Valent Conjugate Vaccine	Invasive Pneumococcal Disease	[Progress bar from Discovery to Phase 3]					VAXCYTE <i>protect humankind</i>
VAX-31	31-Valent Conjugate Vaccine	Invasive Pneumococcal Disease	[Progress bar from Discovery to Phase 2]					
MK-1484	Selective IL-2 Agonist	Advanced or Metastatic Solid Tumors	[Progress bar from Discovery to Phase 1/1B]					MERCK
STRO-003	ROR1 ADC	Solid Tumors & Hematological Cancers	[Progress bar from Discovery to Phase 1/1B]					IPSEN
Undisclosed Programs	Immunostimulatory ADCs (iADCs)	Cancers	[Progress bar from Discovery to Phase 1/1B]					astellas